qPCR assays to quantitate tRNApyl and pylRS expression in engineered cell lines

Andrew Garcia, Gargi Roy, Christine Kiefer, Susan Wilson, Marcello Marelli*

Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America

*marelli.m@medimmune.com

Abstract

Non-natural amino acids (nnAA) contain unique functional moieties that greatly expand the available tool set for protein engineering. But incorporation of nnAAs requires the function of an orthogonal aminoacyl tRNA synthetase/tRNA pair. Stable cell lines expressing these components have been shown capable of producing gram per liter levels of antibodies with nnAAs. However, little has been reported on the genetic makeup of these cells. To gain a better understanding of the minimal requirements for efficient nnAA incorporation we developed qPCR methods for the quantitation of the key components. Here we describe the development of qPCR assays for the quantification of tRNApyl and pylRS. qPCR was chosen because it provides a large dynamic range, has high specificity for its target, and is a non-radioactive method used routinely for cell line characterization. Designing assays for tRNAs present challenges due to their short length (~72 nucleotides) and high secondary structure. These tRNA assays have a $\approx 5$ log dynamic range with the tRNApyl assays being able to discern the mature and unprocessed forms of the tRNApyl. Cell line analysis showed tRNApyl was expressed at higher levels than the CHO-K1 endogenous Met and Phe tRNAs and that $>88\%$ of tRNApyl was the mature form.

Introduction

Over the last ten years bioconjugates have emerged as a promising new class of medicines that offer improved performance of therapeutics. Bioconjugations have been used extensively to improve the half-life of proteins (e.g. PEGylation) and more recently for the construction of antibody drug conjugates (ADCs) [1,2]. ADCs are a promising new class of engineered biotherapeutic that combines the targeting specificity of antibodies with potent cytotoxins for the treatment of cancers. Early ADCs were generated by targeting cysteine thiols, or the primary amine of lysine for payload conjugation. However, this strategy generated heterogenous ADCs that have shown variable payload stability and reduced therapeutic effect [3,4]. To address these limitations technologies have emerged that enable site-specific modifications of target proteins to better control the homogeneity and stability of the products. One of the most attractive methods involves the site-specific incorporation of non-natural amino acids (nnAAs) containing moieties that enable biorthogonal conjugation chemistries [2,5–11].
Biorthogonal conjugation methods including oxime, Diels-Alder and click cycloaddition have all shown efficient conjugate formation and improved stability of the conjugates over the commonly used thiol-maleimide conjugations.

The drawback to using nnAAs lies in the production of proteins containing these nnAAs. Expression systems in *E. coli*, yeast, mammalian cells (CHO and HEK293), and cell free expression systems have been developed and shown efficiency in nnAA incorporation [6, 8, 12–16]. Of these, mammalian cell expressions have the distinct advantage that they conform with conventional fermentation processes, contain a reliable glycosylation pattern, and are generally devoid of endotoxin. Thus, great effort has been dedicated to developing cell lines that are capable of high titer expression of nnAA containing proteins. Stable cell lines expressing orthogonal aminoacyl tRNA synthetase/tRNA pairs have shown yields exceeding 1g/L [7, 17]. However, a good understanding of the minimal expression requirements of aaRS and its tRNA to enable efficient amber suppression is lacking. While the detection and quantification of aaRS expression is straightforward, the same cannot be said of tRNA. The measurement of tRNA is challenging due to its short size, and extensive secondary structure which restricts available qPCR probe sites. In addition, mature cytosolic tRNA, which averages 72 nucleotides is derived from a larger precursor molecule that undergoes 3’ and 5’ processing, and in eukaryotic cells is further modified with a 3’ trinucleotide (CAA) to generate a functional tRNA [18]. Gel based methods requiring hybridization have been used to quantify the expression and assess the level of maturation of tRNAs [19–21]. While this method allows for the quantitation of aminoacylated, free, unprocessed and mature tRNA, it requires radioactive probes and is of low throughput. Molecular approaches to quantify specific tRNAs like four-leaf clover qPCR have been developed, but require large amounts of RNA, has a limited dynamic range, and requires multiple enzymatic steps [22].

We have developed a CHO-based expression system for the expression of biotherapeutics containing nnAAs [7]. The cells utilize the pyrrolysine tRNA synthetase (pylRS), derived from *Methanosarcina mazei*, with specificity for a nnAA and its cognate pyrrolysine tRNA (tRNA-pyl) which directs the nnAA to amber codons in the gene of interest [11]. However, the identification of engineered cells capable of efficient nnAA incorporation required extensive functional screening using reporter constructs to assess amber suppression. The development of these cell lines showed that high tRNA gene copy numbers were needed to achieve the desired nnAA incorporation efficacy in both transient and stable cell lines. To understand the requirements for efficient nnAA incorporation we utilized a qPCR method useful for the quantitation of these genes. The assays were developed to assess both the DNA copy number and RNA expression levels of pylRS and its cognate tRNA-pyl in cell lines capable of amber suppression. This method provides a necessary tool for the characterization of these cells and the determination of the minimum requirements for efficient amber suppression in host cells.

**Materials and methods**

**RNA and DNA isolation**

CHO cells selected for RNA and DNA isolation were grown in suspension in CD-CHO medium (LifeTechnologies) to a viable density of 1–2×10⁶ cells/mL. All cultures were grown at 37°C in shake flasks, in an environment controlled shaking incubator maintaining 6% CO₂, and 80% humidity (Multitron HT, Infors). Culture volumes containing 5×10⁶ cells were subjected to centrifugation, medium was discarded, and pellets frozen at -80°C. Total RNA (tRNA, mRNA and rRNA) was isolated from frozen cell pellets consisting of 5×10⁶ CHO cells using the mirVANA miRNA Isolation kit (Ambion) following the manufacturer’s recommendations. Contaminating DNA was removed from the purified RNA samples using a DNA...
removal kit (Ambion). Genomic DNA (gDNA) was isolated from frozen cell pellets using the AllPrep DNA/RNA Mini Kit (Qiagen). For each gDNA isolation $5 \times 10^6$ cells were lysed in 600μl lysis buffer and purified following the manufacturer’s instructions.

**Plasmid DNA**

pCEP4-pylRS, pylRS gene was cloned under control of the CMV promoter in pCEP4 (LifeTechnologies). pBS-tRNApyl, pBluescript SKII (Stratagene) containing a the tRNApyl gene.

**Primer design and oligomers**

The primers and probes used in this study were custom designed based on available gene sequences. tRNApyl oligo (72bp = $1.35 \times 10^{10}$ copies/ng oligo), tRNApyl unprocessed oligo (87bp = $1.12 \times 10^{11}$ copies/ng oligo), CHO-K1 tRNAmet oligo (72bp = $1.35 \times 10^{10}$ copies/ng oligo) and CHO-K1 tRNAphe oligo (73bp = $1.33 \times 10^{10}$ copies/ng oligo). The primers and probes for CHO-K1 Beta-2 microglobulin (CHO-K1 B2M) were designed by entering a single CHO-K1 B2M exon from GenBank NW_006871970 into ABI’s “Custom Taqman Assay Design Tool.” All DNA oligos were synthesized by IDT and DNA probes were synthesized by ABI. The 18S rRNA (18S) assay was purchased from ABI (Hs999999_01) and used at 1X final concentration in qPCR assays and produces an amplicon of 187bp. No primer sequence information is available for the 18S purchased from ABI.

**qPCR of gDNA**

gDNA samples were analyzed using the Taqman Fast Universal PCR Master Mix (ABI). All assays were performed on the 7900HT Fast Real-Time PCR instrument using a “fast 96 well plate.” Thermocycler conditions were 1 cycle of 95°C for 20sec followed by 40 cycles of 95°C for 1sec and 60°C for 20sec. Each reaction contained 10ng gDNA, 1μM forward primer, 1μM reverse primer and 0.25μM probe. All samples were analyzed in triplicate.

**qRT-PCR of RNA**

RNA samples were analyzed by one-step qRT-PCR method using the Express One-Step SuperScript qRT-PCR with Pre-mixed ROX kit (LifeTechnologies). Reverse Transcription was performed using gene specific primers. For tRNA qRT-PCR, purified total RNA, primers and water were mixed and incubated at 80°C for 5 min, then allowed to cool to room temperature. Buffers and SuperScript qRT were added prior to the qRT-PCR incubations. All assays were performed on the 7900HT Fast Real-Time PCR instrument using a “fast 96 well plate” with each reaction containing 5ng RNA in a 20μl reaction volume. Thermocycler conditions were 1 cycle of 60°C for 15min for Reverse Transcription then 1 cycle of 95°C for 20sec followed by 40 cycles of 95°C for 1sec and 60°C for 20sec. All samples were analyzed in triplicate.

**Cell line construction**

Cell lines stably expressing pylRS and tRNApyl were constructed as described in [7]. Briefly, Chinese hamster ovary cells (CHO), adapted to serum free suspension growth, were transfected with the plasmid pCLD-RS-18xtRNA, encoding pylRS under control of the CMV promoter, 18 tandem repeats of the tRNApyl under control of the U6 snRNA promoter, and a puromycin resistance cassette. Transfected cells were grown in CD-CHO medium containing puromycin and survivors functionally characterized for amber suppression. To do this, mRNA encoding an RFP-GFP fusion, which contains an amber stop codon interrupting the RFP and GFP coding regions, was transfected into these cells. With this reporter all transfected cells
express RFP (RFP+/GFP-), but only cells capable of amber suppression express the RFP-GFP fusion (RFP+/GFP+) that can be readily observed and quantified by flow cytometry. The ratio of GFP:RFP may be indicative of the amber suppression efficacy in each of the cell lines. Thus, cells with the highest GFP:RFP ratios were selected for characterization.

Results

Testing assays for nnAA components on plasmid DNA

We set out to establish assays to determine the gene copy number and relative expression of pylRS and tRNApyl genes in engineered cell lines selected for their activity. While the assay for pylRS is straightforward, the high secondary structure of tRNA posed a challenge for qPCR. Thus, we began by developing a qPCR assay using plasmid DNA encoding the tRNApyl or pylRS as a template. This allowed us to test conditions without the confounding effect of tRNA structure. For each assay gene specific primer sets (Table 1) were used with a titration of the template DNA. The data shows a linear relationship between Ct and the log of plasmid copies ranging from 300 to $3 \times 10^8$ copies for the tRNApyl gene, and 300–$3 \times 10^7$ for pylRS (Fig 1). For reference, 1ng of the pCEP4-pylRS (11,545bp) plasmid represents $8.44 \times 10^7$ copies of the pylRS gene; and 1ng of pBS-tRNApyl (3,287bp) contains $2.97 \times 10^6$ copies of the tRNA gene. In each case we observed a coefficient of determination ($R^2$) approaching 1 and a slope approaching of -3.3. These data show that the qPCR assay has acceptable efficiency through this linear range and indicates that the primer/probe sets are adequate for the qPCR of these genes.

Testing tRNA assays on DNA oligos

Next, we tested the qPCR assay using DNA oligos as templates because they are expected to exhibit secondary structure consistent with cellular samples. In addition, tRNA undergoes

| Table 1. Primers, probes, DNA oligo templates. |
|-----------------------------------------------|
| **tRNApyl**                                    |
| Forward                                       | GGAAACCTGATCATGTAGATCG                           |
| Reverse                                       | GGAAACCCGGGAATC                                 |
| Probe                                         | FAM- ACCCGGGCTGAACGGATTTAGAGTC -TAMRA           |
| tRNApyl unprocessed*                          |
| Reverse                                       | CGCACTTGCAGGAAC                                 |
| **pylRSwt**                                   |
| Forward                                       | ATCAAGCCCATGAGGTC                               |
| Reverse                                       | ACGGCTTCAGGTTCTTC                               |
| Probe                                         | FAM- CCAAGATCTACATCGAGATGGCCTGC -TAMRA          |
| **CHO-K1 tRNAmet**                            |
| Forward                                       | GCAGAGTGCGGCGAC                                 |
| Reverse                                       | TGGTCGATCCATCGACCTTC                             |
| Probe                                         | FAM- GGGCCACAGCACCTGC -TAMRA                    |
| **CHO-K1 tRNAphe**                            |
| Forward                                       | GAAATAGCTCAAGTTGGGAGA                            |
| Reverse                                       | TGAAGCCCGGATCAG                                 |
| Probe                                         | FAM- CGTATAGCTGAGATCTAAAGGTCCCTGG -TAMRA        |
| **CHO-K1 B2M**                                |
| Forward                                       | CGAGCTGTTGAGAATGGGAAGAG                         |
| Reverse                                       | CGTGTGAGCAGAAAAATAGAGAC                         |
| Probe                                         | FAM- ACAAGATGCTGAGCTCAGATCTC-TPQ               |
| **tRNApyl**                                   |
| cDNA                                          | CGGAAACCCGGGAATCGAACCCGGGCTGAACGGATTTAGAGTCATTCCATGGATCTACATGATCGAGGTTCC |
| tRNApyl unprocessed                           |
| cDNA                                          | AAAAAGGCCAAGTCTCCTGCAAGAAGGGCAAGGATTTAGAGTCATTCCATGGATCTACATGATCGAGGTTCC |
| CHO-K1 tRNAmet                                |
| cDNA                                          | TAGCAGAGGATGTTGCTGACTGACCTGCTGGTTAAGTGGGCGAGGACGCCCTCTGGCTGAGGGCATCATGCT |
| CHO-K1 tRNAphe                                |
| cDNA                                          | TGCTGAAACCCGGGCTGAACCGGACCCTTTTAGATCTCAGTCTACATGATCAGCTCCATACAGTATGCTATGAGGCTAAGCT |

*tRNApyl and tRNApyl unprocessed use the same forward primer and probe.

https://doi.org/10.1371/journal.pone.0216356.t001
extensive processing to its mature and active form. Thus, DNA oligos encoding the cDNAs of fully processed mature tRNApyl and the unprocessed tRNApyl were synthesized and used as templates using the primer pairs and probes described above (Fig 2A). Synthesized DNA oligos were the only materials available that we could control for quantity and sequence and are representative of a 100% efficient reverse transcription reaction. Assays for endogenous CHO-K1 tRNAmet and tRNAphe were designed to gauge expression levels of tRNApyl relative to natively expressed tRNAs. CHO-K1 tRNAmet and tRNAphe were chosen for their limited codon representation, specifically tRNAmet has a single codon, ATG, and the tRNAphe has two codons, TTT and TTC. As previously described, the qPCR assays were conducted against a ten-fold serial dilution of DNA oligo spanning 300–3×10^8 copies. All four tRNA assays showed acceptable slope and R^2 values with linearity from 300–3×10^8 DNA oligo copies (Fig 2B–2E).

It should be noted that the amplicon for the tRNApyl assay is contained in both the tRNApyl and tRNApyl unprocessed DNA oligos and will amplify both mature and unprocessed tRNApyl (total tRNApyl). To examine the specificity of the tRNApyl and tRNApyl unprocessed assays, both assays were run against a ten-fold serial dilution of tRNApyl and tRNApyl unprocessed DNA oligos spanning 300–3×10^8 copies of DNA oligo (Table 2). The assay for total tRNApyl yielded similar Ct values for both the tRNApyl and tRNApyl unprocessed DNA oligos. On the other hand, the tRNApyl unprocessed assay shows a significant difference in Ct values between the tRNApyl and tRNApyl unprocessed DNA oligos. The increase in Ct of 13 corresponds to a reduction in sensitivity of 8000-fold, demonstrating that the tRNApyl unprocessed assay is relatively insensitive to mature tRNApyl. Mature tRNApyl levels were therefore calculated as the difference between tRNApyl and tRNApyl unprocessed.

**Testing assays on cell line samples**

Having established a quantitative qPCR assays for both tRNApyl, tRNApyl unprocessed and pylRS on DNA templates, we next set out to establish the conditions for quantifying RNA derived from cellular material derived from a cell line previously characterized for amber suppression activity [7]. For expression analysis this requires the establishment of an RT step to
Fig 2. qPCR assay performance on single stranded DNA oligos corresponding to their target cDNA. (A) Sequence of DNA oligos with the qPCR primers in blue and the qPCR probes in red. 5’-3’ orientation is shown by the direction of the arrows. The position of the primers and probe for both mature and unprocessed tRNApyl are shown on the cloverleaf schematic of the tRNA. The primers for mature tRNApyl quantify total tRNApyl (mature and unprocessed). The reverse primer for unprocessed tRNApyl is specific for this species. (B) tRNApyl assay with the tRNApyl DNA oligo. (C) tRNApyl unprocessed assay with the tRNApyl unprocessed DNA oligo. (D) CHO-K1 tRNAmet assay with the CHO-K1 tRNAmet DNA oligo. (E) CHO-K1 tRNAphe assay with the CHO-K1 tRNAphe DNA oligo. The qPCR assays were tested using a tenfold serial dilution of their respective DNA oligo spanning 300–3×10^8 copies. Plotting the Ct versus the log input of DNA oligo copies show that all qPCR assays have a linear range of 300–3×10^8 with R^2 values approaching 1 and slopes near -3.3.

https://doi.org/10.1371/journal.pone.0216356.g002
convert RNA to cDNA prior to amplification and DNase treatment to remove contaminating genomic DNA. Gene specific primers were used for reverse transcription since the tRNAs have no binding site for oligo dT, and random hexamers do not transcribe all the required tRNA sequences for PCR amplification. As previously mentioned the high secondary structure of tRNA was expected to present a challenge. Indeed, RT-PCR reactions of cellular derived material showed equal values for both mature and unprocessed tRNApyl. The observation that the majority of the tRNApyl was in unprocessed form was contrary to our expectations and we hypothesized that the secondary structure of the mature tRNApyl was inhibiting efficient primer binding. To denature the secondary structure of the tRNApyl prior to RT, an 80˚C incubation step was implemented to allow primer annealing and reverse transcription. Prior to the inclusion of the 80˚C incubation step, the unprocessed form constituted almost 100% of tRNApyl signal obtained. However, after the 80˚C incubation step it accounted for only 10% of tRNApyl signal. This change in percentage of signal from the unprocessed form suggests that the reverse transcriptase step is efficient. The final assay for RNA is a one-step RT-qPCR and the data shown is reported as a ratio relative to 18S ribosomal RNA (18S). For the purposes of our RNA assays we chose to use a single gene, 18S, for normalization. There is always the concern that cell treatment will alter expression levels of your normalizing gene however, in our experience, the high expression of 18S provides a buffer against such variations. Having multiple normalizers (ie GAPDH and 18S) would require extensive effort to make sure that the expression levels of the normalizers are not being differentially impacted by cell treatments. Throughout this manuscript RNA and tRNA expression levels are referred to as expression

### Table 2. Specificity of tRNApyl and tRNApyl unprocessed qPCR assays on single stranded DNA oligo.

| tRNApyl | tRNApyl unprocessed |
|---------|---------------------|
| assay   | assay               |
| tRNApyl | Mean | Std Dev | Mean | Std Dev |
| cDNA oligo | Ct | Ct | Ct | Ct |
| 3x10E8 copies | 10.71 | 0.02 | 24.28 | 0.12 |
| 3x10E7 copies | 14.47 | 0.09 | 27.84 | 0.02 |
| 3x10E6 copies | 17.98 | 0.03 | 31.13 | 0.25 |
| 3x10E5 copies | 21.90 | 0.15 | 34.71 | 0.23 |
| 3x10E4 copies | 25.27 | 0.16 | 37.52 | 0.08 |
| 3x10E3 copies | 28.47 | 0.11 | ND | ND |
| 3x10E2 copies | 31.26 | 0.08 | ND | ND |
| H2O | ND | ND | ND | ND |

| tRNApyl | tRNApyl unprocessed |
|---------|---------------------|
| assay   | assay               |
| tRNApyl unprocessed | Mean | Std Dev | Mean | Std Dev |
| cDNA oligo | Ct | Ct | Ct | Ct |
| 3x10E8 copies | 10.65 | 0.40 | 11.64 | 0.55 |
| 3x10E7 copies | 14.93 | 0.22 | 15.29 | 0.05 |
| 3x10E6 copies | 17.97 | 0.08 | 18.35 | 0.01 |
| 3x10E5 copies | 21.75 | 0.21 | 21.67 | 0.09 |
| 3x10E4 copies | 25.16 | 0.15 | 24.64 | 0.05 |
| 3x10E3 copies | 28.35 | 0.26 | 27.88 | 0.02 |
| 3x10E2 copies | 31.14 | 0.26 | 30.93 | 0.06 |
| H2O | 37.99 | 1.41 | ND | ND |

ND, not detected

https://doi.org/10.1371/journal.pone.0216356.t002
ratios that are calculated using the following formula:

\[
Expression Ratio = 2^{(-\Delta Ct)} \text{ where } \Delta Ct = (\text{Target Mean Ct}) - (18S Mean Ct)
\]

Having established an effective method for measuring both mature and unprocessed tRNA\_pyl total RNA we set out to test the assay on material derived from cells. To do this we isolated RNA from six different clonal cell lines derived from a host capable of amber suppression [7]. Each subclone was initially characterized for amber suppression activity by transfection of an mRNA construct encoding RFP-GFP containing an amber codon between the two fluorescent proteins (Fig 3A). The transfected cells were exposed to nnAA and the fluorescent proteins quantified by flow cytometry (Fig 3B). All transfected cells express the RFP reporter, but only cells capable of amber suppression express an RFP-GFP fusion. The ratio of GFP:RFP may be indicative of the pylRS/tRNA system activity. Thus, six clones (A-F), positive for amber suppression activity, were selected for further study.

**Fig 3.** Quantifying RNA expression levels of unprocessed and mature tRNA\_pyl in cell lines. (A) A reporter mRNA construct was designed to assess amber suppression activity. The reporter encodes an RFP-GFP fusion interrupted by an amber stop codon. All transfected cells show RFP expression, but only amber suppression competent cells express the RFP-GFP fusion. (B) Six clones isolated from an amber suppression competent host were transfected with the RFP-GFP mRNA and exposed to nnAA. Cells were grown for 24 h. and fluorescence expression examined by flow cytometry. Six positive clones showing RFP and GFP signals were identified. A cell line showing no GFP expression is shown for comparison (Neg). (C) RNA from the six amber suppression competent cell lines (A-F) was examined by the tRNA\_pyl and pylRS tRNA\_pyl assays to quantify the extent of tRNA\_pyl processing. The data show that mature tRNA\_pyl constitutes >88% of the tRNA\_pyl forms present in the samples and indicate efficient processing of the tRNA\_pyl in CHO cells.

https://doi.org/10.1371/journal.pone.0216356.g003
suppression, were selected to examine the tRNA and pylRS content. The data show that these stable cell lines have high expression levels of the tRNApyl with ratios relative to 18S ranging from 0.29 to 1.11 and with approximately 90% of the tRNApyl in its mature form (Fig 3C and Table 3). Interestingly, endogenously expressed tRNAphe show expression ratios between $4 \times 10^{-4}$ and tRNAmet between $1.44 \times 10^{-5}$ (Fig 4 and Table 4). These levels are as much as 2000-fold lower than tRNApyl levels indicating that our engineered cells are high expressers of the tRNApyl which may be necessary to enable efficient amber suppression with nnAAs.

**DNA copy number**

Complementary assays to quantify the gene copy number of pylRS using qPCR assays were developed to gain further insight into the content of these engineered cells and examine the relationship between DNA copy number and RNA expression levels of the exogeneous genes. Standard qPCR assays were used for both tRNApyl and pylRS using the same primer sets described above. In addition, a primer set specific for CHO-K1 B2M was synthesized to serve as a standard for genomic copy quantitation (and assuming 2 copies of CHO-K1 B2M per genome). In this text DNA copy number calculations are referred to as Copy Number and are determined with the following formula:

\[
\text{Copy Number} = 2^{(\Delta Ct)} \quad \text{where} \quad \Delta Ct = (\text{Target Mean Ct}) - (\text{CHO K1 B2M Mean Ct})
\]

A gene specific primer set was used with a serial dilution of CHO-K1 genomic DNA spanning 0.025–102.4 ng gDNA. This range reflects the quantities of gDNA that are expected to be loaded into the assay. The CHO-K1 B2M assay has acceptable slope and $R^2$ values with linearity from 0.025–102.4 ng gDNA (Fig 5).

As all the pylRS/tRNApyl expressing cells are from the same parental cell line, the expectation is that there will be no variation on CHO-K1 B2M copy number and all DNA copy number analyses are reported relative to CHO-K1 B2M. Relative copy number was deemed sufficient to examine how the copy number varied among cell lines. Thus, our stable cell lines were analyzed for pylRS and tRNA genomic copies. The data show that the tRNApyl copy number varies substantially from 62–560 copies while the pylRS had a much narrower range from 4–22 copies (Table 5). As the plasmid used for generating this cell line has a 1:18 ratio of pylRS:tRNApyl we expected this ratio to be observed in our stable cell lines (Table 6). Indeed, this ratio is generally retained in all cell lines suggesting that the integrating plasmids are generally intact. Two exceptions, Clone D and Clone F both show greater tRNApyl copy numbers than expected based on the numbers of pylRS indicating that some cell lines may, in the course of integrating the DNA into the genome, introduce only a portion of the tRNApyl containing

| Cell Line | Mean | Std Dev | Expression | Mean | Std Dev | Expression | tRNApyl |
|-----------|------|---------|------------|------|---------|------------|--------|
| clone A   | 17.27| 0.25    | 1.11E+00   | 20.72| 0.34    | 1.02E-01   | 90.8%  |
| clone B   | 18.56| 0.21    | 2.95E-01   | 21.80| 0.27    | 3.11E-02   | 89.5%  |
| clone C   | 16.84| 0.08    | 8.07E-01   | 20.02| 0.26    | 8.96E-02   | 88.9%  |
| clone D   | 17.63| 0.28    | 5.45E-01   | 21.33| 0.40    | 4.18E-02   | 92.3%  |
| clone E   | 17.13| 0.23    | 4.53E-01   | 20.44| 0.34    | 4.55E-02   | 90.0%  |
| clone F   | 16.57| 0.12    | 8.36E-01   | 19.83| 0.17    | 8.69E-02   | 89.6%  |

tRNA expression ratios are reported relative to 18S rRNA.

https://doi.org/10.1371/journal.pone.0216356.t003
Fig 4. Quantifying RNA expression levels of native CHO-K1 tRNAs, tRNAPyl and pylRSwt in engineered cell lines. RNA from six stable cell lines expressing pylRS/tRNAPyl were assayed for endogenous tRNAphe, tRNAmet, as well as tRNAPyl and pylRSwt. The data demonstrate that pylRSwt is expressed at comparable levels to the endogenous CHO-K1 tRNA. tRNAPyl is expressed at ~1000-fold higher levels than endogenous tRNA.

https://doi.org/10.1371/journal.pone.0216356.g004

Table 4. Quantifying RNA expression levels of native CHO-K1 tRNAs, tRNAPyl and pylRSwt in cell lines.

| Cell Line | tRNAPyl assay | tRNAphe assay | tRNAmet assay |
|-----------|---------------|---------------|---------------|
|           | Mean | Std Dev | Expression | Mean | Std Dev | Expression | Mean | Std Dev | Expression |
| clone A   | 17.27 | 0.25 | 1.11E+00 | 27.44 | 0.47 | 9.67E-04 | 26.21 | 0.36 | 2.27E-03 |
| clone B   | 18.56 | 0.21 | 2.95E-01 | 26.99 | 0.39 | 8.55E-04 | 25.31 | 0.33 | 2.73E-03 |
| clone C   | 16.84 | 0.08 | 8.07E-01 | 26.66 | 0.12 | 8.98E-04 | 25.06 | 0.35 | 2.72E-03 |
| clone D   | 17.63 | 0.28 | 5.45E-01 | 27.30 | 0.04 | 6.67E-04 | 25.88 | 0.40 | 1.79E-03 |
| clone E   | 17.13 | 0.23 | 4.53E-01 | 27.04 | 0.19 | 4.71E-04 | 24.75 | 0.14 | 2.30E-03 |
| clone F   | 16.57 | 0.12 | 8.36E-01 | 26.73 | 0.13 | 7.29E-04 | 25.74 | 0.45 | 1.44E-03 |

| pylRSwt assay | 18s assay |
|---------------|-----------|
| Mean | Std Dev | Expression | Mean | Std Dev |
| clone A | 26.55 | 0.27 | 1.79E-03 | 17.42 | 0.15 |
| clone B | 27.60 | 0.08 | 5.58E-04 | 16.80 | 0.02 |
| clone C | 25.86 | 0.18 | 1.56E-03 | 16.34 | 0.10 |
| clone D | 26.78 | 0.26 | 9.58E-04 | 16.75 | 0.22 |
| clone E | 26.40 | 0.13 | 7.32E-04 | 15.98 | 0.04 |
| clone F | 25.00 | 0.07 | 2.42E-03 | 16.31 | 0.10 |

tRNAphe, tRNAmet, tRNAPyl, and pylRSwt expression ratios are reported relative to 18S rRNA.

https://doi.org/10.1371/journal.pone.0216356.t004
plasmid. The tight range of Ct values for CHO-K1 B2M validate the initial assumption that there is no difference in CHO-K1 B2M copies between the cell lines.

We also examined the correlation between DNA copy number and RNA expression level of both tRNApyl and pylRS (Fig 6A). For each cell line the genomic copy number of pylRS and tRNApyl were plotted against their corresponding expression level determine by RT-qPCR. For the most part we observed that cells with increased genetic copy numbers also showed increased expression levels for both pylRS and tRNApyl with notable exceptions. Clones A, B and C showed elevated tRNApyl expression ratios relative to their tRNApyl gene copy numbers; a trend that was also observed with pylRS suggesting that locus of integration may affect expression of these genes.

The biological impact of tRNApyl and pylRS expression on amber suppression efficiency was examined by comparing these levels with the GFP:RFP ratios obtained for each cell line in a functional assay (Fig 3B). The GFP:RFP ratios were determined using the geometric mean data from GFP and RFP by flow cytometry. The GFP levels measure amber suppression while

![Cho-K1 B2M assay](https://doi.org/10.1371/journal.pone.0216356.g005)

**Fig 5.** CHO-K1 B2M assay performance on CHO-K1 genomic DNA. The CHO-K1 B2M qPCR assay was tested against a fourfold serial dilution of CHO-K1 genomic DNA spanning 0.025–102.4 ng gDNA. Graphing the Ct versus the log of plasmid copies demonstrates a linear range of 0.025–102.4 ng gDNA with $R^2$ values approaching 1 and slope values close to -3.3.

https://doi.org/10.1371/journal.pone.0216356.g005

| Cell Line | tRNApyl | pylRSwt | CHO-K1 B2M |
|-----------|---------|---------|------------|
|           | Mean (Ct) | Std Dev (Ct) | Copy (Number) | Mean (Ct) | Std Dev (Ct) | Copy (Number) | Mean (Ct) | Std Dev (Ct) |
| clone A   | 19.75   | 0.16    | 212.1 | 23.91 | 0.03 | 11.9 | 27.48 | 0.08 |
| clone B   | 21.07   | 0.08    | 62.7 | 24.96 | 0.02 | 4.2 | 27.04 | 0.05 |
| clone C   | 20.11   | 0.18    | 142.6 | 24.21 | 0.11 | 8.3 | 27.27 | 0.06 |
| clone D   | 18.63   | 0.22    | 393.1 | 23.63 | 0.10 | 12.3 | 27.25 | 0.04 |
| clone E   | 19.46   | 0.10    | 249.1 | 23.73 | 0.07 | 12.9 | 27.42 | 0.10 |
| clone F   | 18.42   | 0.24    | 560.0 | 23.06 | 0.01 | 22.4 | 27.54 | 0.16 |

Table 5. Quantifying gene copy number in genomic DNA.

DNA copy number was determined relative to CHO-K1 B2M.

https://doi.org/10.1371/journal.pone.0216356.t005
RFP levels represent total expression of the reporter. The ratio of GFP:RFP may be indicative of amber suppression efficacy while accounting for differences in expression of the reporter in the different cell lines. In general, the data shows that higher levels of tRNApyl and pylRS results in increased amber suppression efficacy (Fig 6B and Table 7). It should be noted that transient expression experiments provide a useful, but limited measure of the expression potential of cells due to the short and transient nature of the assay. A better understanding of the true potential of these stable cell lines will need to be assessed using stable expression of very high expressing targets which exceed the capacity of the amber suppression system.

Next, we tested the specificity and reproducibility of the assays. To test specificity, we analyzed RNA and gDNA from a parental cell line (not-transfected with tRNApyl or pylRS) and two clones, clones 1 and 2, created by transfecting the parental cell line with tRNApyl and pylRS (S1 Table). The RNA data for tRNApyl and pylRS show expression in the transfected clones but not in the parental line, while the 18S signal is similar across all three cell lines. The gDNA data yields similar results with tRNApyl and pylRS having good signal in the transfected clones and little to no signal in the parental, while the CHO-K1 B2M signal is similar across all three cell lines. The consistent expression of the normalizer genes combined with the differential expression of tRNApyl and pylRS genes demonstrates that the assays are specific for tRNApyl and pylRS.

To demonstrate the reproducibility of this assay, a single prep of RNA or gDNA, isolated from a transfected cell line, was examined in triplicate on three consecutive days using an identical set up (S2 Table). The Mean Ct and Std Dev Ct values for the triplicates on the plate demonstrate the reproducibility within triplicates. The averages and standard deviations were then calculated across all the days and for each assay. The small standard deviation values for all the assays with RNA and gDNA templates demonstrates the reproducibility of these assays.

**Discussion**

A vast number of nnAAs have been developed that provide building blocks for protein engineering with unique functional chemistries. This repertoire of nnAAs provides a means for the generation of protein therapeutics with enhanced functionality, and thus hold great promise in producing and potentiating new drugs for the treatment of human disease. However, despite significant advances, the productivity of systems capable of site-specific nnAA incorporation has prevented its widespread use. Genetically encoding nnAA, in both in vitro and in vivo systems, requires the concerted function of an orthogonal aminoacyl tRNA synthetase and its cognate tRNA. In vitro expression systems have successfully addressed many of the limitations, but this methodology requires dedicated cell free expression facilities [8]. On the other hand, cell-based systems have been developed that show potential for producing at levels

| Cell Line | pylRSwt observed | tRNApyl observed | tRNApyl predicted |
|-----------|------------------|------------------|------------------|
| clone A   | 11.9             | 212.1            | 214.2            |
| clone B   | 4.2              | 62.7             | 75.8             |
| clone C   | 8.3              | 142.6            | 149.3            |
| clone D   | 12.3             | 393.1            | 221.7            |
| clone E   | 12.9             | 249.1            | 232.2            |
| clone F   | 22.4             | 560.0            | 402.7            |

Copy numbers are reported relative to CHO-K1 B2M.

[https://doi.org/10.1371/journal.pone.0216356.t006](https://doi.org/10.1371/journal.pone.0216356.t006)
consistent with manufacturing standards. These can be used with conventional fermentation facilities and methodologies, but require engineered cells, carefully selected for high amber suppression potential.

While it is clear that an orthogonal tRNA synthetase and its cognate tRNA must be expressed by the host cells, the expression levels of these genes required for efficient nnAA incorporation remain largely unknown. This is, in part, due to the difficulties in quantifying tRNA levels which previously relied largely on Northern analyses and more recently on molecular methods which require multiple enzymatic steps [20–22]. Hence, we have developed a qPCR-based method for the quantitation of tRNApyl and pylRS that enable the rapid characterization of cell lines. The assays described here show a $>5$ log dynamic range and are

![Graphs showing DNA copy number to RNA expression ratio for tRNApyl and pylRSwt assays.](https://doi.org/10.1371/journal.pone.0216356.g006)
effective at quantifying both RNA and gDNA. Engineered cell lines functionally characterized for efficient nnAA incorporation, contained 4–22 copies of pylRS and 65–560 copies of tRNA. More impressively we noted that expression levels of the tRNA approached that of the ribosomal 18S rRNA. This expression level is over 1000-fold greater than pylRS and the endogenous Phe and Met tRNAs. This high level of tRNA may be necessary to compete with release factor (eRF1) for amber codon recognition. eRF1 mediates the process of protein termination by recognizing stop codons and promoting the release of the polypeptide chain by the ribosome [23–24]. Thus, high levels of tRNApyl are likely needed to compete for amber codon binding and readthrough. Indeed, cells with higher levels of pylRS and tRNA expression show improved amber suppression efficacy using a transiently expressed reporter construct. However, it should be noted that the assay provides a relative quantitation of tRNApyl and pylRS expression levels which is useful for the discrimination of cell lines. That said, analyses of technical replicates show consistent results suggesting that the qPCR method is both robust and reproducible (S2 Table).

Beyond quantifying the tRNA, qPCR allows us to examine the extent of tRNApyl processing. In our cells tRNApyl expression is under control of a PolIII promoter that regulates the expression of a transcript that requires both 3’ and 5’ processing that is required to generate functional tRNApyl. The assays developed here discriminate between unprocessed and mature (functional) tRNApyl allowing for an assessment of tRNA functionality. In the cells tested we observed ~90% mature tRNA indicating that processing of this tRNA is efficient despite the high expression levels. Overall, the methodology described provides us with a tool for the characterization of cells containing aaRS/tRNA based systems as well as a key metric for cell line selection. The analysis of six cell lines showed a relationship between copy number and expression levels. Two notable exceptions for tRNApyl indicate that site of integration influences expression of these genes and highlights that copy number alone is not a predictive metric for tRNA expression. In addition, we show that increased amber suppression efficacy is observed in cells with higher levels of the pylRS/tRNApyl. Future studies with additional cell lines or other platforms are needed to better establish this relationship. As we develop new engineered cell lines the minimal requirements of tRNA and pylRS for efficient nnAA incorporation at >1g/L yields of target will become evident. One area of import is the genetic stability of the pylRS/tRNApyl system which must support efficient amber suppression over 70 generations in a manufacturing setting. The assay developed here is an invaluable tool in assessing the genetic stability of the system considering the highly repetitive nature of the tRNApyl cassettes and their potential for recombination. Overall the assay is readily applicable to the quantitation

### Table 7. Comparing cell line RNA expression of tRNApyl and pylRS to GFP:RFP ratio.

| Clone | tRNApyl | pylRS | GFP | RFP | GFP:RFP ratio |
|-------|---------|-------|-----|-----|--------------|
| A     | 1.11E+00| 1.79e-03| 114 | 1103| 0.103        |
| B     | 2.95E-01| 5.58e-04| 82  | 3054| 0.027        |
| C     | 8.07E-01| 1.56e-03| 158 | 506 | 0.312        |
| D     | 5.45E-01| 9.58e-04| 149 | 1570| 0.095        |
| E     | 4.53E-01| 7.32e-04| 111 | 3829| 0.029        |
| F     | 8.36E-01| 2.42e-03| 148 | 456 | 0.325        |
| Neg   | ND      | ND    | 14  | 931 | 0.015        |

Expression levels of tRNApyl and pylRS are reported relative to 18S rRNA. Geometric means of GFP and RFP were quantified by flow cytometry. ND, not detected.

https://doi.org/10.1371/journal.pone.0216356.t007
of exogenous aaRS/tRNAs and offers a tool to better understand the limitations of these nnAA incorporation systems.

**Supporting information**

S1 Table. Data table examining the specificity of the qPCR assays. (DOCX)

S2 Table. Data table examining the reproducibility of the qPCR assays. (DOCX)

**Author Contributions**

*Conceptualization:* Andrew Garcia, Christine Kiefer, Marcello Marelli.

*Formal analysis:* Andrew Garcia, Marcello Marelli.

*Investigation:* Andrew Garcia, Gargi Roy.

*Methodology:* Andrew Garcia.

*Supervision:* Susan Wilson, Marcello Marelli.

*Writing – original draft:* Marcello Marelli.

*Writing – review & editing:* Gargi Roy, Marcello Marelli.

**References**

1. Hu QY, Berti F, Adamo R. Towards the next generation of biomedicines by site-selective conjugation. Chemical Society Reviews. 2016; 45: 1691–719. https://doi.org/10.1039/c4cs00388h PMID: 26796469

2. Hallam TJ, Wold E, Wahl A, Smider V V. Antibody conjugates with unnatural amino acids. Mol Pharm. 2015; 12: 1848–1862. https://doi.org/10.1021/acs.molpharmaceut.5b00082 PMID: 25898256

3. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin cancer Res. 2004 10: 7063–70. https://doi.org/10.1158/1078-0432.CCR-04-0789 PMID: 15501986

4. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008; 26: 925–32. https://doi.org/10.1038/nbt.1480 PMID: 18641636

5. Wang A, Naim N, Marelli M, Grabstein K. Protein engineering with non-natural amino acids. In: Kaumaya P, editor. InTechOpen; 2012; 253–90. https://doi.org/10.5772/28719 Available from: https://www.intechopen.com/books/protein-engineering/protein-engineering-with-non-natural-amino-acids.

6. Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A. 2014; 111: 1766–71. https://doi.org/10.1073/pnas.1321237111 PMID: 24443552

7. VanBrunt MP, Shanebeck K, Caldwell Z, Thompson P, Martin T, Dong H, et al. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody – Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjug Chem. 2015; 26: 2249–2260 https://doi.org/10.1021/bc500490z PMID: 26332743

8. Zimmerman ES, Heibek TH, Gill A, Li X, Murray CJ, Madiansacay MR, et al. Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem. 2014; 25: 351–61. https://doi.org/10.1021/bc400490z PMID: 24437342

9. Li X, Liu Z, Dong S. Bicyclo[6.1.0]nonyne and tetrazine amino acids for Diels–Alder reactions. RSC Adv. 2017; 7: 44470–3. https://doi.org/10.1039/C7RA08136G

10. Plasse T, Milles S, Koehler C, Schultz C, Lemke EA. Genetically encoded copper-free click chemistry. Angew Chem Int Ed Engl. 2011; 50: 3878–81. https://doi.org/10.1002/anie.201008178 PMID: 21433234

11. Wan W, Tharp JM, Liu WR. Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool. Biochim Biophys Acta. 2014; 1844: 1059–70. https://doi.org/10.1016/j.bbabio.2014.03.002 PMID: 24631543
12. Xie J, Schultz PG. A chemical toolkit for proteins—An expanded genetic code. Nature Reviews Molecular Cell Biology. 2006; 7: 775–82. https://doi.org/10.1038/nrm2005 PMID: 16926858

13. Nguyen DP, Lusic H, Neumann H, Kapadnis PB, Deiters A, Chin JW. Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolysyl-tRNA synthetase/tRNA(CUA) pair and click chemistry. J Am Chem Soc. 2009; 131: 8720–1. https://doi.org/10.1021/ja900553w PMID: 19514718

14. Kiick KL, Saxen E, Tirrell DA, Bertozzi CR. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci. 2002; 99: 19–24. https://doi.org/10.1073/pnas.012583299 PMID: 11752401

15. Hancock SM, Uprety R, Deiters A, Chin JW. Expanding the genetic code of yeast for incorporation of diverse unnatural amino acids via a pyrrolysyl-tRNA synthetase/tRNA pair. J Am Chem Soc. 2010; 132: 14819–24. https://doi.org/10.1021/ja104609m PMID: 20925334

16. Mukai T, Kobayashi T, Hino N, Yanagisawa T, Sakamoto K, Yokoyama S. Adding l-lysine derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. Biochim Biophys Acta. 2008; 1771: 818–22. https://doi.org/10.1016/j.bbrc.2008.04.164 PMID: 18471995

17. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012; 109: 16101–6. https://doi.org/10.1073/pnas.1211023109 PMID: 22988081

18. Hopper AK, Pai DA, Engelke DR. Cellular dynamics of tRNAs and their genes. FEBS Letters. 2010; 584: 310–7. https://doi.org/10.1016/j.febslet.2009.11.053 PMID: 19931532

19. Serfling R, Lorenz C, Etzel M, Schicht G, Böttke T, Mör M, et al. Designer tRNAs for efficient incorporation of non-canonical amino acids by the pyrrolysine system in mammalian cells. Nucleic Acids Res. 2018; 46: 1–10. https://doi.org/10.1093/nar/gkx1156 PMID: 29177436

20. Kohrer C, Sullivan EL, RajBhandary UL. Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. Nucleic Acids Res. 2004; 32: 6200–11. https://doi.org/10.1093/nar/gkh959 PMID: 15576346

21. Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. RNA. 2008; 14: 2407–16. https://doi.org/10.1261/rna.1208808 PMID: 18796578

22. Honda S, Shigematsu M, Morichika K, Telonis AG, Kirino Y. Four-leaf clover qRT-PCR: A convenient method for selective quantification of mature tRNA. RNA Biol. 2015; 12: 501–8. https://doi.org/10.1080/15476286.2015.1031951 PMID: 25833336

23. Wong LE, Li Y, Pillay S, Frolova L, Pervushin K. Selectivity of stop codon recognition in translation termination is modulated by multiple conformations of GTS loop in eRF1. Nucleic Acids Res. 2012; 40: 5751–65. https://doi.org/10.1093/nar/gks192 PMID: 22383581

24. Kryuchkova P, Grishin A, Eliseev B, Karyagina A, Frolova L, Alkalaeva E. Two-step model of stop codon recognition by eukaryotic release factor eRF1. Nucleic Acids Res. 2013; 41: 4573–86. https://doi.org/10.1093/nar/gkt113 PMID: 23435318